- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05417945
A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System
June 9, 2022 updated by: Jenscare Scientific
A Prospective, Multicenter, Single-group Target Value Clinical Study to Evaluate the Safety and Efficacy of JensClip Transcatheter Valve Repair System in the Treatment of Moderate to Severe Degenerative Mitral Regurgitation
The clinical trial study is designed as a prospective, multicenter, single-group target value clinical study to evaluate the safety and efficacy of the clinical investigational product and to evaluate its performance using the above clinical trial primary endpoint and secondary endpoint indicators.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Transcatheter mitral valve repair system is derived from the "Edge-to-Edge" technique in traditional surgery.
The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.
Study Type
Interventional
Enrollment (Anticipated)
124
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shengshou Hu
- Phone Number: 18616900716
- Email: guyongxin@jenscare.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years;
- Echocardiographically confirmed moderate-severe or severe degenerative mitral regurgitation (regurgitation degree MR ≥ 3+);
- NYHA Classification II-IV.
- LVEF ≥ 20%
- Patients considered at high surgical risk after evaluation by two or more cardiovascular specialists (American Association for Thoracic Surgery STS score: risk of death from mitral valve repair ≥ 6% or from mitral valve replacement ≥ 8% (high risk); or the presence of 2 or more indices of frailty (moderate to severe frailty); or the presence of 2 or more major organ insufficiencies that do not improve postoperatively; or a comprehensive cardiac team assessment that the patient has other combined diseases or factors that make him or her unsuitable for surgery)
- Anatomically suitable for mitral valve repair and assessed as suitable for use of this investigational device.
- Voluntarily participate and sign an informed consent form and be willing to accept relevant examinations and clinical follow-up.
Exclusion Criteria:
- Severe mitral valve calcification
- Previous implantation of a prosthetic mitral valvuloplasty ring or prosthetic mitral valve, or previous transcatheter mitral valve surgery
- Patients with active infective endocarditis
- Patients with mitral stenosis
- Any intracardiac mass, left ventricular or atrial thrombus detected by echocardiography
- Severe coronary stenosis without surgical or interventional treatment or an acute myocardial infarction within 90 days
- Combined with tricuspid, aortic valve or severe macrovascular pathology requiring surgical or interventional treatment
- Severe pulmonary hypertension (pulmonary artery systolic pressure > 70 mmHg measured by ultrasound or right heart catheter, if measured at the same time the right heart catheter measurement shall prevail).
- Patients with severe right heart insufficiency
- Hemodynamic instability, defined as systolic blood pressure <90 mmHg in the absence of afterload-reducing drugs, cardiogenic shock, or use of intra-aortic balloon pump;
- Had a stroke/transient ischemic attack (TIA) within 30 days or severe carotid stenosis (> 70% stenosis on ultrasonography)
- Have undergone transcatheter cardiovascular intervention (PCI) within 30 days, or cardiovascular surgery within 180 days
- Have had a pacemaker or cardioverter-defibrillator (ICD) implanted, or have undergone cardiac resynchronization therapy (CRT, CRT-D) within 30 days
- Patients with clear coagulation disorders and severe coagulation disorders, or with clear contraindications to the anticoagulant drugs
- Known hypersensitivity to product composition
- Patients with severe neurological pathology affecting cognitive ability
- Patients with a life expectancy of < 12 months
- Have undergone a heart transplant or have recently been allocated a heart transplant donor
- Being enrolled in an interventional clinical study of another device or drug
- Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis), dilated cardiomyopathy, or constrictive pericarditis
- Patients who are pregnant or planning to become pregnant within the next 12 months. Note: Female patients of childbearing age are required to undergo a pregnancy test within 14 days prior to the operation and the result should be negative, and additionally they should use a confirmed method of contraception
- Other conditions that the investigator considers inappropriate for participation in this clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JensClip transcatheter valve repair system
Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.
|
Transcatheter mitral valve repair system is derived from the "Edge-to-Edge" technique in traditional surgery.
The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success rate at 12 months postoperatively
Time Frame: 12 months
|
Clinical success is defined as no death, no mitral valve-related surgical procedures due to mitral valve incompetence, and no moderate-severe or severe mitral regurgitation (MR > 2+), with the primary evaluation indicators determined by the Core Laboratory and Clinical Event Committee (CEC).
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shengshou Hu, FUWAI YUNAN CARDIOVASCULAR HOSPITAL
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2022
Primary Completion (Anticipated)
May 1, 2024
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
June 6, 2022
First Submitted That Met QC Criteria
June 9, 2022
First Posted (Actual)
June 14, 2022
Study Record Updates
Last Update Posted (Actual)
June 14, 2022
Last Update Submitted That Met QC Criteria
June 9, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT-2021-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Regurgitation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Medtronic CardiovascularRecruitingMitral Valve RegurgitationUnited States, Canada, Denmark
-
Heart Repair Technologies, Inc.Na Homolce HospitalTerminatedMitral RegurgitationCzechia
-
Abbott Medical DevicesAbbottActive, not recruitingMitral Regurgitation | Mitral Valve RegurgitationUnited States, Canada, Spain, Israel, Germany, Italy, Japan, France, Netherlands, Saudi Arabia
-
Duk-Woo Park, MDCardioVascular Research Foundation, KoreaCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve RegurgitationKorea, Republic of
-
Abbott Medical DevicesAbbottCompletedMitral Regurgitation | Mitral Valve RegurgitationNetherlands, United Kingdom, United States, Spain, Israel, Germany, Italy, Switzerland
-
IRCCS Policlinico S. DonatoActive, not recruitingMitral RegurgitationItaly
Clinical Trials on JensClip transcatheter valve repair system
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingMitral Valve Insufficiency
-
Edwards LifesciencesActive, not recruitingTricuspid Valve InsufficiencySwitzerland, Germany, Greece, Italy
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral InsufficiencySwitzerland, Germany, Austria, Greece, Italy, Netherlands, Poland, Spain, United Kingdom
-
Xijing HospitalNot yet recruitingTricuspid Regurgitation
-
Edwards LifesciencesActive, not recruiting
-
Hangzhou Valgen Medtech Co., LtdEnrolling by invitationDegenerative Mitral Valve DiseaseChina
-
Edwards LifesciencesActive, not recruitingMitral Valve InsufficiencySwitzerland, Germany
-
Michele De BonisCompletedMitral Valve RegurgitationItaly
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hangzhou Valgen Medtech Co., LtdRecruitingMitral Regurgitation FunctionalChina